The relationship between PD-1 gene single nucleotide polymorphism and long-term survival in non-small cell lung cancer patients
10.3760/cma.j.cn431274-20230609-00836
- VernacularTitle:非小细胞肺癌患者PD-1基因单核苷酸多态性与远期生存的关系
- Author:
Junpei WU
1
;
Quan FANG
;
Xiaodan ZHU
Author Information
1. 浙江中医药大学研究生院，杭州 310053
- Keywords:
Carcinoma, non-small-cell lung;
Programmed cell death 1 receptor;
Polymorphism, single nucleotide;
Progression-free survival
- From:
Journal of Chinese Physician
2024;26(4):568-572
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the relationship between single nucleotide polymorphism of programmed cell death 1 (PD-1) gene and long-term survival in non-small cell lung cancer (NSCLC) patients.Methods:Eighty NSCLC patients admitted to the Yiwu Central Hospital from June 2020 to June 2022 were selected. Polymerase chain reaction restriction fragment length polymorphism was used to detect the PD-1.1 (rs36084323) and PD-1.5 (rs2227981) polymorphisms in the peripheral blood of the patients. Follow-up statistics were conducted on the progression free survival (PFS) and overall survival (OS) of NSCLC patients. We also analyzed the correlation between PD-1 genotype and clinical parameters in non-small cell lung cancer patients. And Cox univariate and multivariate analyses were used to evaluate the influencing factors of PFS and OS in NSCLC patients.Results:The proportion of PD-1.1 AA, AG, and GG genotypes in NSCLC patients was 30.00%, 50.00%, and 20.00%, respectively, while the proportion of PD-1.5 CC, CT, and TT genotypes in NSCLC patients was 55.00%, 38.75%, and 6.25%, respectively. The differences were not statistically significant (all P>0.05). PD-1.1 genotype was correlated with differentiation degree ( P<0.05); PD-1.5 genotype was associated with lymph node metastasis ( P<0.05). The median PFS of patients with PD-1.1 genotype AA, AG, and GG were 15.00(95% CI: 1.65-28.35)months, 15.00(95% CI: 10.53-19.47)months, and 11.00(95% CI: 5.12-16.88)months, respectively. The median OS was 30.00(95% CI: 23.58-36.42)months, 31.00(95% CI: 29.45-32.56)months, and 22.00(95% CI: 11.56-32.44)months, respectively. There was no statistically significant difference in PFS and OS among the three genotypes (all P>0.05). The median PFS of patients with PD-1.5 locus CC and CT+ TT genotypes were 18.00(95% CI: 12.47-23.53)months and 10.00(95% CI: 6.47-13.53)months, respectively. The median OS was 32.00(95% CI: 29.86-34.14)months and 22.00(95% CI: 15.25-28.75)months, respectively, and the differences were statistically significant (all P<0.05). The Cox multivariate analysis results showed that clinical stage, lymph node metastasis, and PD-1.5 locus genotype were independent influencing factors for PFS in NSCLC patients (all P<0.05); Age, clinical stage, lymph node metastasis, and PD-1.5 locus genotype are independent influencing factors for OS (all P<0.05). Conclusions:The PD-1.5 locus polymorphism is associated with long-term survival in NSCLC patients, providing new research ideas for the mechanism research and targeted therapy of NSCLC.
